Safety of smoking cessation drugs for mentally ill patients
Mené auprès de 8 144 fumeurs dont 4 116 présentant des troubles psychiatriques, cet essai compare l'efficacité, du point de vue du taux d'abstinence tabagique, et les effets neuropsychiatriques de la varénicline, du bupropion et du patch nicotinique
In The Lancet, Robert Anthenelli and colleagues1 report the results of a large multi-site, double-blind, triple-dummy, randomised, placebo-controlled trial comparing the neuropsychiatric safety risk and efficacy of varenicline and bupropion with nicotine patch and placebo in two separate cohorts of smokers: one with current or past psychiatric disorders (n=4074) and one without (n=3984). The trial was requested by the US Food and Drug Administration (who also consulted on the study design) and was funded by the manufacturers of bupropion and varenicline.
The Lancet , commentaire, 2015